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Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive human cancers. Several
studies have reported that the carbohydrate antigen 19-9 (CA19-9) level is a useful marker for predicting the
prognosis for PDAC after resection. However, the cutoff value of CA19-9 used to predict prognosis varied among
these reports. The aims of this study were to evaluate whether the serum CA19-9 level is a significant predictor for
survival and to determine the optimal cutoff value of CA19-9 for predicting prognosis.
Methods: A total of 120 consecutive patients who underwent surgery for potentially resectable primary PDAC were
retrospectively analyzed. The variables included the following: age, sex, the location of the tumor, the maximal
tumor size, the histological differentiation, the margin status, the tumor stage, serum CA19-9 levels, and serum total
bilirubin (TBil) levels.
Results: The overall 1-year survival rate was 62.5%. The receiver operating characteristic (ROC) curve indicated a
significant result for the level of CA19-9 in predicting death within 1 year after surgery (Area under the curve (AUC),
0.612; 95% confidence interval (CI), 0.505-0.720; P = 0.040). The optimal cutoff point was 338.45 U/mL (sensitivity,
60.0%; specificity, 66.7%; accuracy, 64.2%). The strongest univariate predictor among the categorized CA19-9 values
was CA19-9 greater than or equal to 338.45 U/mL. In the multivariate Cox proportional hazards mode analysis, the
serum CA19-9 level, age and the histological differentiation were significant independent prognostic factors that
were associated with the overall survival.
Conclusions: The preoperative elevated CA19-9 level is a promising independent factor for predicting a poor
prognosis in PDAC, and the optimal cutoff value is 338.45 U/mL.
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Overall survival (OS)Background
Pancreatic cancer is one of the most aggressive human
cancers and is characterized by a rapid tumor spread
and a dismal prognosis [1]. By the time of diagnosis,
fewer than 15% of patients can be offered a potential
curative treatment, and up to 30% of the patients die* Correspondence: dongqian08@163.com
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reproduction in any medium, provided the orwithin 12 months [2,3]. Additionally, the 5-year survival
rate of patients with potentially resectable pancreatic
cancer was reported not to exceed 20% [4]. It is ex-
tremely important to precisely predict the prognosis
after tumor resection for the assessment of the thera-
peutic effect, for the consideration of administering ad-
juvant therapy, and to provide information to patients.
To date, several studies have reported that the pre-
operative carbohydrate antigen 19-9 (CA19-9) level,
which is a tumor-associated antigen that requires the
expression of a sialylated Lewis blood group antigen fortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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after resection [5-13]. However, the cutoff value of
CA19-9 used to predict prognosis varied among these
reports. A value of 37 U/mL has been frequently used as
the cutoff value in previous studies [7,10,14,15]. The
normal physiological level of serum CA19-9 is defined
as under 37 U/mL, which was estimated based on the
standard deviation of the distribution of serum CA19-9
levels among normal persons. Serum CA19-9 levels are
elevated in 70% to 80% of pancreatic cancer patients
[16] and may be more suitable for the diagnosis of pan-
creatic cancer rather than for predicting the prognosis
for the patients with established diagnosis. Thus, it is
still uncommon for clinicians to predict prognosis with
preoperative CA19-9 values.
The aims of this study were to evaluate whether the
preoperative CA19-9 value is a significant predictor for
survival and to determine the optimal cutoff value of
CA19-9 for predicting the prognosis in PDAC.
Methods
Patients and methods
From 1 January 2009 to 28 February 2011, 139 consecu-
tive patients underwent surgery for potentially resectable
primary pancreatic ductal adenocarcinoma (PDAC) at the
Shengjing Hospital of China Medical University. In all of
the patients, the PDAC was histologically confirmed.
Patients with other pancreatic malignancies, such as intra-
ductal papillary mucinous adenocarcinoma, acinar cell
carcinoma, adenosquamous carcinoma, mucinous carcin-
oma, and malignant endocrine tumors, were excluded
from this study. The patients had not received chemother-
apy or radiation therapy prior to surgery.
The variables included the following: age, sex, the lo-
cation of the tumor (head, body or tail of the pancreas),
the maximal tumor size (cm), histological differentiation
(well, moderately or poorly differentiated), the margin
status (positive or negative), the tumor stage, the node
stage, the TNM stage, preoperative serum CA19-9 levels,
and preoperative serum total bilirubin (TBil) levels. The
maximal tumor size was defined as the maximum diam-
eter on pathological analysis. The margins assessed in-
cluded the pancreatic resection margin, the biliary
margin, the posterior margin, the retroperitoneal margin,
and the mesenteric margin. The tumors were staged ac-
cording to the TNM criteria of the American Joint Com-
mittee on Cancer (AJCC) 2010 staging system [17].
All of the serum CA19-9 levels were measured within
2 weeks before surgery with an electrochemiluminescence
immunoassay using the Roche Cobas E601 (Roche,
Switzerland) immunoassay system. The upper limit of the
normal reference value for CA19-9 is 37 U/mL. The pre-
operative TBil levels were detected concurrently with the
CA19-9 levels using a vanadic acid oxidation method withthe Abbott ARCHITECT ci1600 (Abbott, USA) automatic
analyzer. Altered biliary excretion, for which bilirubin is
reasonable marker, has been documented to occur at levels
1.5× the upper limit of the normal reference value or at a
level of approximately 34.2 μmol/L (2.0 mg/dL) [18].
The patients themselves or the clinicians and relatives
of the patients were contacted by telephone and inter-
viewed for patient survival or the documented day of
death. The final survival data were collected on May 15,
2013. The median follow-up period was 15.0 months
(range, 1.4 to 52.0 months). Adjuvant chemotherapy
with a standard regimen was performed on all of the pa-
tients who were able to tolerate postoperative chemo-
therapy regardless of the margin status or tumor stage.
Nineteen of the 139 patients were excluded from the
present analysis for the following reasons: six patients
(4.3%) died in the hospital within 30 days after the sur-
gery; the clinicopathological characteristics and progno-
sis were not available for six patients (4.3%); and seven
patients (5.0%) had a preoperative CA19-9 value of <2
U/mL and were judged to be non-secretors of CA19-9
[6]. Ultimately, 120 patients were analyzed. All of the pa-
tients’ data were retrospectively reviewed after approval
from the Research Ethics Committee of Shengjing Hos-
pital of China Medical University.
Statistical analysis
The continuous variables such as age, serum CA19-9 and
TBil levels, and follow-up periods were expressed as me-
dians with ranges. The patients who were alive at the last
follow-up were censored. The comparisons between clini-
copathological characteristics and the CA19-9 values were
performed with a Mann-Whitney U test or a Kruskal-
Wallis H test if the grouping variables were more than two.
Overall survival (OS) was defined as the time from the date
of the surgery to either the date of death from any cause or
the last contact, that is, the date of the last follow-up visit.
The cutoff points to categorize the serum CA19-9 levels
were obtained as follows: (1) the upper limit of the normal
reference value for CA19-9 (37 U/mL); (2) the mean value
of CA19-9; (3) the median value of CA19-9; (4) the receiver
operating characteristic (ROC) curve was used to assess the
ability of CA19-9 to predict for 1-year death and to deter-
mine the optimal cut-off point of CA19-9; (5) additional
cutoff points were chosen based on data previously pub-
lished by other groups (200 U/mL and 1000 U/mL)
[7,19,20]. The categorization divided the patients into those
less than versus those greater than or equal to the indicated
cutoff points. Different categorizations of the preoperative
values of CA19-9 divided by the above six cutoff points
were examined. The survival curve was calculated using the
Kaplan-Meier estimate. The survival differences between
subgroups of patients were analyzed by the log-rank test.
The strongest univariate predictor among the categorized
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Cox proportional hazards model (forward) was fitted using
all of the clinical and pathological variables, which included
age, gender, the location of the tumor, the maximal tumor
size, the histological differentiation, the surgical margins,
the pT category, the pN category, the pTNM category,
serum TBil level, and CA19-9 with the optimal cutoff value.
The corresponding hazard ratios (HRs) and their 95% con-
fidence intervals (CIs) were calculated. SPSS software ver-
sion 13.0 (SPSS Inc., Chicago, IL, USA) was used for the
statistical analysis. Two-sided P values less than 0.05 were
considered to be statistically significant.Table 1 The relationship between serum CA19-9 levels and cl
surgical resection
Characteristics Number (n =
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Demographic and clinicopathological characteristics
One hundred and twenty patients were included in this
study. Table 1 lists the demographic and clinicopatho-
logical characteristics of these 120 patients. The median
age was 60 years (range, 35 to 80 years), and 67 (55.8%)
of the patients were men. The tumors of 92 (76.7%) pa-
tients were primarily located at the pancreas head, and
28 (23.3%) tumors were located at the pancreas body or
tail. The median size of the tumors was 4.0 cm (range,
1.2 to 10 cm). Regarding the histological differentiation,
41 (34.2%) patients had a well-differentiated tumor, 68inicopathological factors in 120 cases of PDAC treated by
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and 11 (9.1%) had a poorly differentiated tumor. One
hundred and fourteen (95.0%) patients had negative sur-
gical margins, and 39 (32.5%) patients were positive for
nodal metastasis. Sixty-two (51.7%) patients had tumors
that extended beyond the pancreas.
The clinicopathological characteristics versus serum
CA19-9 levels
As shown in Table 1, the serum CA19-9 levels were
strongly associated with the histological differentiation,
and the median CA19-9 levels increased with the tumor
grade (P = 0.024). The median CA19-9 value was higher
in the group with a TBil level of ≥34.2 μmol/L than in
the group with a TBil level <34.2 μmol/L (P = 0.025).
The median CA19-9 levels were different between the
patients with T1/T2 and T3/T4, but no statistical signifi-
cance was observed (P = 0.055).
Comparisons among the cutoff points of CA19-9 values
The mean and the median values of CA19-9 were 617.31
U/mL and 287.61 U/mL, respectively. The overall 1-year
survival rate was 62.5%. Forty-five patients died within the
first year after the surgery to resect the tumor. Figure 1
shows the ROC curve for the 1-year death and the CA19-9
levels. The ROC analysis indicated a significant result for
the level of CA19-9 in predicting death within 1 year after
surgery (Area under the curve (AUC), 0.612; 95% CI,
0.505-0.720; P = 0.040). The optimal cutoff point was
338.45 U/mL (Youden index, 0.27; sensitivity, 60.0%; speci-
ficity, 66.7%; accuracy, 64.2%). The sensitivity, specificity,Figure 1 ROC curve for the 1-year death. AUC with the 95% CI is
noted in the graph inset; the P value is with regard to testing the
prognostic accuracy against the null hypothesis (area = 0.5).and accuracy for 37 U/mL as the cutoff point were 91.1%,
18.7%, and 45.8%, respectively. Table 2 summarizes the uni-
variate tests for all of the categories considered for overall
survival. As shown in Table 2, the strongest univariate pre-
dictor among the categorized CA19-9 values was a level of
CA19-9 <338.45 U/mL. The patients with a level of CA19-
9 <338.45 U/mL had a median overall survival time of 24.9
months compared with 11.9 months for patients with a
level of CA19-9 ≥338.45 U/mL (log rank x2, 6.868; P =
0.009) (Figure 2).
Multivariate Cox proportional hazards model analysis of
the prognostic factors for overall survival
The multivariate Cox proportional hazards model (forward)
was fitted using all of the clinical and pathological variables,
which included age, gender, the location of the tumor, the
maximal tumor size, the histological differentiation, the sur-
gical margins, the pT category, the pN category, the pTNM
category, serum TBil level, and serum CA19-9 level. In the
multivariate Cox proportional hazards model (forward)
analysis, a CA19-9 level ≥338.45 U/mL (HR, 1.961; 95% CI,
1.241-3.099; P = 0.004), an age ≥60 years (HR, 0.554;
95% CI, 0.351-0.874; P = 0.011), a histologically moderately
differentiated tumor (compared with well-differentiated,
HR, 2.108; 95% CI, 1.251-3.551; P = 0.005), and a histologi-
cally poorly differentiated tumor (compared with well-
differentiated, HR, 4.393; 95% CI, 1.932-9.986; P = 0.000),
were significant independent prognostic factors associated
with overall survival (Table 3).
Discussion
The tumor-associated CA19-9 antigen has been ac-
cepted as the most meaningful tumor marker for pan-
creatic cancer. Its clinical usefulness in the diagnosis
[21], the assessment of resectability [14], monitoring the
progression [11] and determining the prognosis of pan-
creatic cancer has been reported [7-13]. Ferrone et al.
[20] reported that the preoperative level of CA19-9 was
not an independent prognostic factor in patients with re-
sectable pancreatic adenocarcinoma. However, a contra-
dictory result has been revealed by the Waraya [10],
Hartwig [22], and Hirakawa [15] groups, arguing that
the preoperative CA19-9 level is an independent prog-
nostic factor on multivariate analysis. The result from
our study is consistent with the latter findings. Accord-
ing to the ROC curve analysis and the multivariate Cox
proportional hazards model analysis, we found that the
preoperative CA19-9 level is a promising predictor for
the overall survival or prognosis of PDAC.
Although it has been accepted that the level of CA19-
9 can be used as a valuable predictor for the prognosis
of PDAC, the cutoff value of CA19-9 is still controver-
sial. Waraya et al. [10] and Hirakawa et al. [15] reported
that a level of CA19-9 >37 was the independent
Table 2 Univariate analysis of the overall survival of two groups divided on the basis of the CA19-9 cutoff value in
patients with PDAC treated by resection
Cutoff value (U/mL) Number (n = 120) Median OS (months) Log rank x2 P value
<37 18 21.6 6.647 0.010
≥37 102 14.2
<200 52 19.2 2.105 0.147
≥200 68 13.9
<287.61 60 19.2 3.923 0.048
≥287.61 60 12.7
<338.45 68 24.9 6.868 0.009
≥338.45 52 11.9
<617.31 79 19.2 4.696 0.030
≥617.31 41 12.0
<1,000 93 15.9 0.827 0.363
≥1,000 27 12.0
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detectable preoperative CA19-9 levels and a value of
CA19-9 >200 U/mL were related to survival. A value of
50 U/mL was used by Kang et al. [23], while Hartwig
et al. [22] reported that a level of CA19-9 ≥400 was an
independent negative predictor. The cutoff values of
CA19-9 used in previous studies were varied. Among
them, a value of 37 U/mL was most frequently used.
This cutoff value is also recommended as the upper limit
of the normal range for CA19-9, which is elevated in
70% to 80% of pancreatic cancer patients. However, in
our clinical practice, it has been found that a few pa-
tients did not yet have poor prognoses as predicted afterFigure 2 Comparison of the overall survival between the two groups se
difference in survival was revealed by the log-rank test (P = 0.009).a regular surgical resection and routine chemotherapy,
although a level of CA19-9 >37 U/mL was observed in
these patients. Using 37 U/mL of CA19-9 as the cutoff
value may be more suitable for the diagnosis of pancre-
atic cancer rather than predicting a prognosis for the pa-
tients with an established diagnosis. In this study, an
attempt to determine the optimal cutoff value was car-
ried out, with comparisons made among six cutoff
points. The optimal cutoff point was 338.45 U/mL based
on the ROC curve analysis, and the specificity and ac-
curacy were increased compared with using 37 U/mL as
the cutoff point. Moreover, the relationship between
these six CA19-9 cutoff points and overall survival wasparated by the CA19-9 cutoff value of 338.45 U/mL. A significant
Table 3 Significant independent prognostic factors for overall survival in patients with PDAC treated by resection on
multivariate analysisa
Characteristics Category Hazard ratio 95% CI P value
Age (years) ≥60 vs. <60 0.554 0.351-0.874 0.011
Histological differentiation well 1 0.001
moderately 2.108 1.251-3.551 0.005
poorly 4.393 1.932-9.986 0.000
CA19-9 (U/mL) ≥338.45 vs. <338.45 1.961 1.241-3.099 0.004
aThe multivariate Cox proportional hazards model (forward) was fitted using all of the clinical and pathological variables, which included age, gender, location of
tumor, maximal tumor size, histological differentiation, surgical margins, pT category, pN category, pTNM category, serum TBil level, and CA19-9 level.
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that the strongest univariate predictor is a level of
CA19-9 ≥338.45 U/mL. According to the multivariate
Cox proportional hazards model analysis, a preoperative
CA19-9 value ≥338.45 U/mL is also a significant inde-
pendent prognostic factor for a poor prognosis in
PDAC.
As an important marker of PDAC, the serum CA19-9
level can be influenced by other factors. One of the most
common factors may be the histological differentiation
of the tumor cells, which is considered to be a character-
istic of malignancy. It has been suggested that an altered
secretion or distribution pattern in pancreatic tumors
leads to the differential levels of the tumor-associated
CA19-9 antigen in the serum [24]. Thus, the CA19-9
levels may vary with the characteristics of the tumor
cells. In this study, the CA19-9 levels were strongly asso-
ciated with histological differentiation. Similar to the
study by Rahbari et al. [25], the age, differentiation, and
the CA19-9 levels were revealed to be independent pre-
dictors for overall survival with a multivariate analysis.
The CA19-9 level has been reported to correlate with
tumor burden [18], but in our present study, a contra-
dictory result was observed: the CA19-9 levels did not
correlate with the tumor size or the amount of tumor
cells. The findings indicate that CA19-9 is a characteris-
tic of the tumor cells in PDAC, which may reflect the se-
cretion capacity and the malignant biological behavior of
the tumor.
Although, the median CA19-9 value was higher in the
group with a TBil level ≥34.2 μmol/L than in the group
with a TBil level <34.2 μmol/L, the TBil level was not a
prognostic predictor of overall survival according to the
multivariate analysis. In addition, for the median serum
TBil level, there were no differences between the pa-
tients with a CA19-9 level ≥338.45 U/mL and those with
a level of CA19-9 <338.45 U/mL (P = 0.062). Similar to
our results, Hartwig et al. [14] reported that hyperbiliru-
binemia did not markedly affect the CA19-9 levels.
In the present study, neither the tumor size nor grade
was the independent prognostic predictor, which was con-
sistent with Berger et al. [26] but discrepant with Warayaet al. [10]. The relationships between the tumor size or
grade and the outcome of PDAC have produced mixed re-
sults. Though the tumor size and grade may represent
some aspects of the malignancy of the tumor, there are also
other aspects that determine the malignancy of the tumor,
for example, the histological differentiation. In this study,
the most significant prognostic predictor was the histologi-
cally poorly-differentiated tumor (HR, 4.393; P = 0.000).
Thus, the relationships between the tumor size or grade
and the outcome of PDAC could be clarified in the further
prospective validation, including an adequate number of
patients.
Ferrone et al. [20] reported that the surgical margin
was not an independent prognostic predictor for the pa-
tients with resectable PDAC, which was consistent with
the result of the present study. However, Kinsella et al.
[27] reported that the surgical margin was an independ-
ent prognostic factor. The discrepancies among the
studies that assess the relationship of surgical margin
and survival may be due to the different therapeutic ap-
proaches and pathology reporting. The contents of the
margin assessed in the study of Kinsella et al. contained
pancreatic neck, uncinate process, the common bile
duct, portal vein groove, anterior soft tissue and poster-
ior soft tissue margins of excision, which were different
from that of the present study. On the other hand, the
extent of the margin clearance was associated with the
survival [28]. In addition, the molecular-genetic evalu-
ation of surgical margin could improve pathological sta-
ging and prognostic evaluation of patients with PDAC
[29]. Kim et al. [29] reported that K-ras gene mutation
in histologically negative surgical margins associated
with poor outcome of patients with PDAC. Therefore,
the relationships between the surgical margin and the
prognosis of patients with resectable PDAC could be in-
vestigated in the further prospective studies, in which all
of the factors above mentioned should be taken into
account.
Lastly, inevitable limitations exist in the present study as
a pilot study. First, the follow-up period is one of the great-
est concerns. PDAC is the type of disease that has a dismal
prognosis with a 5-year survival rate of approximately 5%
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of patients, is required to clarify the relationship between
the preoperative CA19-9 value and prognosis. Another
concern of this study is the CA19-9 factor; the level of
CA19-9 may oversimplify the prediction of prognosis for
PDAC, and in the future, more extensive factors should be
explored.
Conclusions
In conclusion, a preoperative CA19-9 value ≥338.45 U/mL
was shown to be a promising independent factor for a poor
prognosis in PDAC on univariate and multivariate analysis.
The preoperative CA19-9 level may be clinically useful for
a prognostic valuation in cases of resectable PDAC. CA19-
9 levels appear to have a useful place in the strategic plan-
ning for the management of patients with PDAC.
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